Metraipolis › archive › dc_a333c8680d45

Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic-Epigenetic Effects of Its Pharmacological Inhibition — Europe PMC PMID:41596241

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41596241
DOI
10.3390/ijms27020589
License (as archived)
solo-consultazione
Archived
2026-11-07T00:42:32.812Z
SHA-256 of the archived text
12ee17d26def298b000367300907d2e8f10975644c5eb75062b60248597ba7b2
Stable URL of this page
https://metraipolis.com/documento/dc_a333c8680d45

How to cite

Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic-Epigenetic Effects of Its Pharmacological Inhibition — Europe PMC PMID:41596241 — Europe PMC (en), https://europepmc.org/article/MED/41596241 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a333c8680d45 (Metraipolis archive dc_a333c8680d45, sha256 12ee17d26def298b000367300907d2e8f10975644c5eb75062b60248597ba7b2)
BibTeX
@misc{dca333c8680d45,
  title = {Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic-Epigenetic Effects of Its Pharmacological Inhibition — Europe PMC PMID:41596241},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41596241},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a333c8680d45; sha256 12ee17d26def298b000367300907d2e8f10975644c5eb75062b60248597ba7b2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41596241. Agents can read the archived copy with the MCP tool read_document.